Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC
Recruiting
Phase 4
Interventional Study
Cirrhosis
HCC - Hepatocellular Carcinoma
Portal Vein Thrombosis
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 70
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 100 (estimated)
- Sponsor
- Mansoura University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
We will give an anticoagulant against portal vein thrombosis, and watch for the results.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Portal vein thrombosis, Cirrhosis, With or without HCC, Child A \& B
Exclusion Criteria:
* Platelets\<10000, Createnine \>1.9, Budd ciarri, Uncontrolled active bleeding
Contacts